2023-510356-23-00招募中1 期
Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 76
- 试验地点
- 14
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Novartis Pharma Arzneimittel GmbH
Scientific
Novartis Pharma AG
研究点 (14)
Loading locations...
相似试验
招募中
1 期
A Phase 1 Prospective, Open-label, First-in-human Study to Evaluate the Safety, Tolerability and Biodistribution of [177Lu]Lu-AKIR001 and its Anti-tumour Effect in Adult Patients with CD44v6 Expressing Solid Tumours2023-508126-95-00Karolinska University Hospital30
招募中
3 期
Ulcerative Colitis: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects with Moderately to Severely Active Ulcerative ColitisUlcerative Colitis2022-501788-41-00Abbvie Deutschland GmbH & Co. KG40
招募中
1 期
BY002 IIT Study in R/R Acute LeukemiaAcute LeukemiaNCT07270770The First Affiliated Hospital of Soochow University18
已完成
1 期
A randomized, open-label, single dose, cross-over study to evaluate the drug-drug interaction between Proscar 5 mg, film-coated tablets and Cialis 5 mg film-coated tablets when co-administered versus the administration of each product alone in healthy volunteers under fasting conditions. Study no. FIN-TAD-DDI-03-242024-510774-24-00Adamed Pharma S.A.30
招募中
2 期
A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and PharmacokineticsNCT07260500Changchun GeneScience Pharmaceutical Co., Ltd.72